Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Biotech (5)
- Research (4)
- DNA (2)
- Development (2)
- Genetics (2)
-
- IP (2)
- Patent (2)
- Protection (2)
- Transgenic (2)
- Algorithms (1)
- Artificial insemination (1)
- Biomedicine (1)
- Biotechnological advancement (1)
- Biotechnology (1)
- CDNA (1)
- Cancer (1)
- Cell line (1)
- Cloning (1)
- Commercialization (1)
- Conflict of interest research (1)
- Copyright (1)
- Cutting edge (1)
- Decision making (1)
- Ecology (1)
- Embryo (1)
- Fertility (1)
- Fetal tissue (1)
- GMO (1)
- Genes (1)
- Genetic engineering (1)
Articles 1 - 13 of 13
Full-Text Articles in Life Sciences
Normalizing Novelty: Regulating Biotechnological Risk At The U.S. Epa, Les Levidow, Susan Carr
Normalizing Novelty: Regulating Biotechnological Risk At The U.S. Epa, Les Levidow, Susan Carr
RISK: Health, Safety & Environment (1990-2002)
Drs. Levidow and Carr examine EPA's regulation of biotechnology in the field of genetically modified organisms.
Genome Research And Traditional Intellectual Property Protection -- A Bad Fit?, Kate H. Murashige
Genome Research And Traditional Intellectual Property Protection -- A Bad Fit?, Kate H. Murashige
RISK: Health, Safety & Environment (1990-2002)
Dr. Murashige addresses the need for a patent system more closely tailored to the needs of biotechnology. For example, the obviousness requirement may interfere with using patents to recoup high costs of work when it could arguably be done by researchers of ordinary skill.
Maximizing The Return From Genome Research: Introduction, Thomas G. Field Jr.
Maximizing The Return From Genome Research: Introduction, Thomas G. Field Jr.
RISK: Health, Safety & Environment (1990-2002)
Professor Field introduces and explains the origins of the symposium.
Biotechnology Process Patents: Is Special Legislation Needed?, Timothy P. Linkkila, Timothy E. Tracy
Biotechnology Process Patents: Is Special Legislation Needed?, Timothy P. Linkkila, Timothy E. Tracy
RISK: Health, Safety & Environment (1990-2002)
The authors review administrative and court decisions prompting proposed changes to the patent law. After reviewing pros and cons, they argue that, on balance, pending bills can easily cause more problems than they solve.
Origins Of The Human Genome Project, Robert Mullan Cook-Deegan
Origins Of The Human Genome Project, Robert Mullan Cook-Deegan
RISK: Health, Safety & Environment (1990-2002)
Dr. Cook-Deegan recounts some of the scientific and political history leading to controversy about the proper mix of private and public roles in pursuing genome research and bringing its fruits to bear, e.g., in preventing and curing disease.
Overview Of Potential Intellectual Property Protection For Biotechnology, Kate H. Murashige
Overview Of Potential Intellectual Property Protection For Biotechnology, Kate H. Murashige
RISK: Health, Safety & Environment (1990-2002)
Dr. Murashige compares the function and value of copyright, patent and trade secret laws in recovering investments in developing genome-related biotechnology.
Book Review, Bradley J. Olson
Book Review, Bradley J. Olson
RISK: Health, Safety & Environment (1990-2002)
Review of: JOHN HARRIS, WONDERWOMAN AND SUPERMAN: THE ETHICS OF HUMAN BIOTECHNOLOGY. (Oxford University Press 1992) [271 pp.] Acknowledgements, further reading, index, introduction, notes. LC 91-23939; ISBN 0-19-2177540-0. [$22.95 cloth. 200 Madison Avenue; New York NY 10016.]
Book Review, Gianna Julian-Arnold
Book Review, Gianna Julian-Arnold
RISK: Health, Safety & Environment (1990-2002)
Review of the following: BIOMEDICAL POLITICS. (Kathi E. Hanna, ed., National Academy Press 1991) [352 pp.] Preface and acknowledgements, Carl W. Gottschalk, Chair, Institute of Medicine Committee to Study Biomedical Decision Making. Appendices, biographical notes on authors and commentators, index, notes, references. LC 91- 18394, ISBN 0-309-04486-3. [Cloth $29.95. Export $36.00. 2101 Constitution Ave., NW, Washington DC 20418.]
Old Remedies In The Biotechnology Age: Moore V. Regents, Michelle J. Burke, Victoria M. Schmidt
Old Remedies In The Biotechnology Age: Moore V. Regents, Michelle J. Burke, Victoria M. Schmidt
RISK: Health, Safety & Environment (1990-2002)
The California Supreme Court, by excluding a potential remedy, has eliminated many concerns generated by a lower court decision resolving rights to the cell line derived from John Moore's spleen. Yet, the Supreme Court gave little attention to remedies that remain. The authors argue that a constructive trust, a remedy of considerable vintage and great flexibility, could be applied to achieve a just result in such circumstances without affecting the biotechnology world at large.
Book Review, Mark G. Bloom
Book Review, Mark G. Bloom
RISK: Health, Safety & Environment (1990-2002)
Review of the following book: WARREN FREEDMAN, LEGAL ISSUES IN BIOTECHNOLOGY AND HUMAN REPRODUCTION. (Quorum Books 1991) [240 pp.] Appendices, bibliography, index to cases, index to subjects. LC: 90-20709; ISBN: 0-89930-635-7. [Cloth $55.00. 88 Post Road West, Westport, CT 06881]
Book Review, Allan M. Wheatcraft
Book Review, Allan M. Wheatcraft
RISK: Health, Safety & Environment (1990-2002)
Review of the following book: SHELDON KRIMSKY, BIOTECHNICS AND SOCIETY: THE RISE OF INDUSTRIAL GENETICS. (Praeger 1991) [280 pp.] Bibliography, figures, index, list of acronyms used, tables. LC: 90-23214, ISBN: 0-275-93860-3. [Paper $17.95. P.O.B. 5007, Westport CT 06881.]
Book Review, Bradley J. Olson
Book Review, Bradley J. Olson
RISK: Health, Safety & Environment (1990-2002)
BIOTECHNOLOGY: ASSESSING SOCIAL IMPACTS AND POLICY IMPLICATIONS. (David J. Webber, ed., Greenwood Press 1990) [239 pp.] Bibliography, contributor data, index, notes, preface, tables. LC: 90-2935; ISBN: 0-313-27454-1. [Cloth. $42.95. P.O.B. 5007, Westport, CT 06881]
Federal Technology Transfer: Should We Build Subarus In Bethesda, Christopher J. Harnett
Federal Technology Transfer: Should We Build Subarus In Bethesda, Christopher J. Harnett
RISK: Health, Safety & Environment (1990-2002)
A critical examination of a policy designed to encourage commercial exploitation of federally funded biomedical research. The author argues that the implementation of this policy threatens the integrity of basic science in America.